The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Cited by
Sorted by citations
Items 701–800 of 1,000
Mazein, A., Lopata, O., Reiche, K., Sewald, K., Alb, M., Sakellariou, C. A., Gogesch, P., Morgan, H., Neuhaus, V., Pham, N.-N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601670 · Cited by 9
Dimitrov, K., Merkle, F., Dimitrov, M., Merkle, S., Hoover, A., & Bachanová, V. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.07.005 · Cited by 9
Naik, S., Aplenc, R., Baumeister, S. H. C., Becilli, M., Bhagwat, A. S., Bonifant, C. L., Budde, L. E., Chien, C. D., Curran, K. J., Daniyan, A. F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017011 · Cited by 9
Self-citationTumor-derived extracellular vesicles: Bridging communication and next-generation theranostics
Chen, J., Verdiell, A., Formoso, C., Luciano, M., Chen, C. T., & Thakur, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118815 · Cited by 9
Cardiotoxicity of T cell immunotherapies
Raddatz, M. A., Stein-Merlob, A. F., Mahmood, S. S., Ganatra, S., Addison, D., Lin, T. L., Larson, S. M., & Yang, E. H. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01265-z · Cited by 9
Management of Cytokine Release Syndrome
Varadarajan, I., Kindwall‐Keller, T. L., & Lee, D. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00005-6 · Cited by 9
Abdel‐Azim, H., Dave, H., Jordan, K. R., Rawlings-Rhea, S. D., Luong, A., & Wilson, A. L. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.08.007 · Cited by 9
Deng, P., Jiang, J., Hu, C., Cao, L., & Li, M. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i5.1580 · Cited by 9
Zeng, K., Huang, M., Lyu, M.-A., Khoury, J. D., Ahmed, S., Patel, K. K., Dropulić, B., Reese‐Koc, J., Caimi, P. F., Sadeghi, T., et al. (2023) · Cells · doi:10.3390/cells12141880 · Cited by 9
CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas
Das, A. K., Sinha, M., Singh, S. K., Chaudhary, A., Boro, A. K., Agrawal, M., Bhardwaj, S., Kishore, S., & Kumari, K. (2024) · Acta Neurologica Belgica · doi:10.1007/s13760-024-02519-8 · Cited by 9
Meanwatthana, J., & Majam, T. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211000691 · Cited by 9
Gerard, E., Zohar, S., Lorenzato, C., Ursino, M., & Riviere, M. (2021) · Statistics in Medicine · doi:10.1002/sim.9113 · Cited by 11
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential
DePriest, B. P., Vieira, N., Bidgoli, A., & Paczesny, S. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1992276 · Cited by 9
Future Developments in the Treatment of AL Amyloidosis
Theodorakakou, F., Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Hemato · doi:10.3390/hemato3010012 · Cited by 9
Adoptive Immunotherapy for the Treatment of Glioblastoma: Progress and Possibilities
Kuramitsu, S., Yamamichi, A., Ohka, F., Motomura, K., Hara, M., & Natsume, A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0076 · Cited by 9
Wu, X., Shi, B., Zhang, J., Shi, Z., Di, S., Fan, M., Gao, H., Wang, H., Gu, J., Jiang, H., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.026 · Cited by 9
CAR emissions: cytokines tell the story
Maude, S. L. (2017) · Blood · doi:10.1182/blood-2017-10-808592 · Cited by 9
Self-citationEngineered T Cell Therapies from a Drug Development Viewpoint
Chen, F., Fraietta, J. A., June, C. H., Xu, Z., Melenhorst, J. J., & Lacey, S. F. (2018) · Engineering · doi:10.1016/j.eng.2018.11.010 · Cited by 9
Self-citationA giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Zhao, H., Wang, Y., Yin, E. T. S., Zhao, K., Hu, Y., & Huang, H. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0808-3 · Cited by 9
Liu, J., Xia, Y., Mog, B. J., Gliech, C. R., Shaw, E. R., Ferris, D. P., McGahan, A., Cleage, K. A., Moritz, B., Kaeo, K. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.19.682634 · Cited by 9
Chimeric Antigen Receptor Cells Solid Tumor Immunotherapy Assisted by Biomaterials Tools
Song, Y., Wang, Y., Man, J., Xu, Y., Zhou, G., Shen, W., Chao, Y., Yang, K., Pei, P., & Hu, L. T. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20275 · Cited by 8
Xu, Z., Wang, R., Xu, Y., Qiu, R., Chen, J., Liu, L., & Qian, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-89686-7 · Cited by 8
Barker, K. N., Marco, T., Husnain, M., & Katsanis, E. (2025) · Cancers · doi:10.3390/cancers17060918 · Cited by 8
Advanced biomaterials and delivery modalities to alleviate cancer therapy-induced inflammation
Huang, H., Ke, Q., Li, T., Yang, Z., Shen, J., Li, Z., Zeng, Q., Wei, X., Yang, H., Wang, D., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123419 · Cited by 8
Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations
Fløe, L. V. B., Pedersen, M. G., & Møller, B. K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189455 · Cited by 9
McNerney, K. O., Diorio, C. J., Annesley, C., Gardner, R. A., Graham, A. K., Sanchez-Pinto, L. N., Ombrello, A. K., Talleur, A. C., Chaudhury, S., Schultz, L. M., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.09.028 · Cited by 8
Self-citationLinz, C., Shimabukuro‐Vornhagen, A., Hesse, N., Probst, L., Borrega, J. G., Eichenauer, D. A., Kochanek, M., von Bergwelt‐Baildon, M., & Böll, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209967 · Cited by 8
Shah, M., Rajha, E., Dinardo, C. D., Muckey, E., Wierda, W. G., & Yeung, S. J. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.015 · Cited by 8
Toxicity of Chimeric Antigen Receptor T Cells and its Management
Wudhikarn, K., Soh, S. Y., Huang, H., & Perales, M. (2021) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2021-011 · Cited by 8
Management of CAR T-cell Related Toxicities
Murthy, H. S., Yassine, F., Iqbal, M., Alotaibi, S., Moustafa, M. A., & Kharfan‐Dabaja, M. A. (2022) · Hematology/Oncology and Stem Cell Therapy · doi:10.56875/2589-0646.1029 · Cited by 8
Advances in CAR T cell immunotherapy for paediatric brain tumours
Rao, P., Furst, L. M., Meyran, D., Mayoh, C., Neeson, P. J., Terry, R. L., Khuong-Quang, D.-A., Mantamadiotis, T., & Ekert, P. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873722 · Cited by 10
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines
Shang, S., Chen, Y., Yang, X., Yang, Y., Wang, W., & Wang, Y. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01344-9 · Cited by 8
Yeung, C. C. S., Woolston, D. W., Wu, V., Voutsinas, J. M., Basom, R., Davis, C., Hirayama, A. V. V., & Naresh, K. N. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14068 · Cited by 8
Zhang, P., Ying, P.-T., Li, H., Zhao, N., Liu, R., Li, S., Xu, W., Tang, Y., & Tang, Y. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01925-2 · Cited by 9
Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy
Dou, B.-T., Ren, S.-H., Qiu, L., Zhang, X., Zhang, N., Cai, J., Chen, D., Zhang, Q., Yao, H., & Fan, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1265835 · Cited by 8
Balasubramanian, A., Veluswami, K., Rao, S., Aggarwal, S., & Mani, S. (2024) · Cureus · doi:10.7759/cureus.64324 · Cited by 9
Cai, W., Lu, Y., He, H., Li, J., Liu, S., Geng, H., Yang, Q., Zeng, L., Wu, D., & Li, C. (2024) · Oncology Letters · doi:10.3892/ol.2024.14817 · Cited by 8
Application of Chimeric Antigen Receptor-Engineered T Cells in Ovarian Cancer Therapy
Zhang, M., Zhang, B., & Shi, H. (2017) · Immunotherapy · doi:10.2217/imt-2017-0039 · Cited by 8
Outsmarting and outmuscling cancer cells with synthetic and systems immunology
Chen, L. C., & Chen, Y. Y. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.016 · Cited by 8
Machowicz, R., & Basak, G. W. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15226 · Cited by 8
Melody, M. E., Rahman, Z. A., Saunders, H., Lengerke-Diaz, P. A., Gannon, N., Rosenthal, A. C., Ayala, E., Tun, H. W., Murthy, H. S., Roy, V., et al. (2020) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2020.09.004 · Cited by 8
Janus Kinase Inhibitors and Cell Therapy
Assal, A., & Mapara, M. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740847 · Cited by 8
Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy
Lebedeva, А., Molodtsov, I. A., Anisimova, A., Berestovskaya, A., Dukhin, O., Elizarova, A., Fitzgerald, W., Fomina, D. S., Glebova, K. A., Ivanova, O., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147937 · Cited by 8
Moghimi, B., & Barrett, D. M. (2017) · Current Stem Cell Reports · doi:10.1007/s40778-017-0101-9 · Cited by 8
Self-citationA Model-Based Investigation of Cytokine Dynamics in Immunotherapies
Hopkins, B., Pan, Y., Tucker, M., & Huang, Z. J. (2018) · Processes · doi:10.3390/pr7010012 · Cited by 8
Ragoonanan, D. S., Sheikh, I. N., Gupta, S. K., Khazal, S. J., Tewari, P., Petropoulos, D., Li, S., & Mahadeo, K. M. (2022) · Biomedicines · doi:10.3390/biomedicines10092286 · Cited by 8
Si, L., Wei, D., Pan, J., Baleeiro, R. B., Chard, L. S., & Wang, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218240 · Cited by 7
Barber-Rotenberg, J. S., Haas, A. R., Aggarwal, C., O’Hara, M. H., Hexner, E. O., Pequignot, E. C., Dowd, E., Ndeupen, S., Thai, E., Chen, F., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.021 · Cited by 7
Self-citationFarias, M. G., Vicente, B. D. M., Habigzang, M. D. O., Hirakata, V. N., da Silva, P. D. O., Paz, A. A., & Daudt, L. E. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101543 · Cited by 7
Cao, X., Li, J., Lu, P., & Liu, K.-Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03398-6 · Cited by 7
An integrated perspective on measuring cytokines to inform CAR-T bioprocessing
Williamson, H. K., & Mendes, P. M. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108405 · Cited by 7
Marschollek, P., Liszka, K., Mielcarek‐Siedziuk, M., Dachowska-Kałwak, I., Haze, N., Panasiuk, A., Olejnik, I., Jarmoliński, T., Frączkiewicz, J., Gamrot, Z., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12071622 · Cited by 8
Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more
Castro, J. E., & Kipps, T. J. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.08.011 · Cited by 8
Gupta, R., Roach, C., Hryniewicki, A. T., Vilke, G. M., Shatsky, R. A., & Coyne, C. J. (2020) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2020.04.021 · Cited by 7
Tocilizumab for severe COVID-19 related illness – A community academic medical center experience
Meleveedu, K. S., Miskovsky, J., Meharg, J. V., Abdelrahman, A., Tandon, R., Moody, A. E., Dasilva, P., Masse, G., LaPorte, J. P., Calvino, A. S., et al. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100035 · Cited by 7
Secondary hemophagocytic syndrome in adult patients. Study of 91 patients
Потапенко, В. Г., Климович, А. В., Pervakova, M. Y., Lapin, S. V., Goloshchapov, O. V., Titov, A., Суркова, Е. А., Pavluchenko, E., Александровна, П. Н., Vinogradova, N. V., et al. (2020) · Oncohematology · doi:10.17650/1818-8346-2020-15-4-52-64 · Cited by 7
Jayakumar, I., Uppuluri, R., Lakshmanan, C., Gowdhaman, A. K., Swaminathan, V. V., & Raj, R. (2020) · Pediatric Transplantation · doi:10.1111/petr.13964 · Cited by 7
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia
Fabrizio, V. A., & Curran, K. J. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101305 · Cited by 7
Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic
Fathi, M., Vakili, K. G., Jazi, K., Sadeghi, M. A., Hajiesmaeili, M., Mohamadkhani, A., Rezaei–Tavirani, M., & Tavasol, A. (2021) · Tumori Journal · doi:10.1177/03008916211063939 · Cited by 7
Strategies to overcome the side effects of chimeric antigen receptor T cell therapy
Godarzee, M. M., Hussen, B. M., Razmara, E., Hakak‐Zargar, B., Mohajerani, F., Dabiri, H., Rasul, M. F., Ghazimoradi, M. H., Babashah, S., & Sadeghizadeh, M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14724 · Cited by 7
Hafez, W., Ziade, M. A., Arya, A., Saleh, H., Abdelshakor, M., Alla, O. F., Agrawal, P., Ali, S., Rao, S. R., Gupta, S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11020241 · Cited by 7
Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients
Knight, J. M., Taylor, M. R., Rentscher, K. E., Henley, E., Uttley, H. A., Nelson, A. M., Turcotte, L. M., McAndrew, N. S., Amonoo, H. L., Mohanraj, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877558 · Cited by 7
Foster, M. R., Negash, Y., Eberhardt, L., Bryan, W. W., Schultz, K., Wang, X., Xu, Y., & George, B. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.006 · Cited by 7
Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy.
Kravets, V. G., Zhang, Y., & Sun, H. (2017) · PubMed · Cited by 7
Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia
Keiffer, G., French, Z., Wilde, L. R., Filicko-O'Hara, J. E., Gergis, U. S., & Binder, A. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.562625 · Cited by 7
Koukoulias, K., Παπαδοπούλου, Α., Kouimtzidis, A., Papayanni, P. G., Papaloizou, A., Sotiropoulos, D., Yiangou, M., Costeas, P., Anagnostopoulos, Α., Yannaki, E., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17464 · Cited by 7
Kollu, V. S., Mott, S. L., Khan, R., Farooq, U., Jethava, Y. S., İnce, D., & Tricot, G. J. K. (2018) · Cureus · doi:10.7759/cureus.2945 · Cited by 7
Zavras, P. D., Wang, Y., Gandhi, A. P., Lontos, K., & Delgoffe, G. M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s177844 · Cited by 9
Influence of CAR T-cell therapy associated complications
Umair, M., Lai, X., Xue, Y.-B., & Yao, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1494986 · Cited by 6
Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL
McNerney, K. O., & Schultz, L. M. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.02.016 · Cited by 6
Ma, X., He, H., Zhu, Y., Zuo, D., Wang, F., Feng, M., Ji, K., & Chen, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625813 · Cited by 6
Moreno‐Castaño, A. B., Fernández, S., Brillembourg, H., Iraola, G., Moreno, D. F., Ventosa-Capell, H., Martínez-Sánchez, J., Moner, B. D., Molina, P., Ramos, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664788 · Cited by 6
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
Schultz, L. M., McNerney, K. O., Lamble, A. J., Calkoen, F., Baruchel, A., Ceppi, F., Curran, K. J., Gore, L., Lamb, M. G., Maude, S. L., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01115-w · Cited by 6
Self-citationJin, J., Liu, T., Cheng, J., Meng, J., Wang, N., Huang, L., Zhou, X., Chen, L., Luo, H., & Zhou, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03418-2 · Cited by 6
Taheri, S. (2022) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.390259 · Cited by 6
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma
Balushi, K. A. A., Hadhrami, A. A., Balushi, H. A., Lawati, A. A., & Das, S. (2023) · Current Drug Targets · doi:10.2174/0113894501280380231214105255 · Cited by 6
Perils and Problems in Bispecific T-Cell Engager Antibodies
Bisht, K., & Kumar, J. R. (2024) · Current Drug Safety · doi:10.2174/0115748863286774240219094217 · Cited by 6
Balestra, T., Niswander, L. M., Bagashev, A., Loftus, J. P., Ross, S. L., Chen, R. K., McClellan, S. M., Junco, J. J., López, D. A. B., Rabin, K. R., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02493-3 · Cited by 7
Burleigh, K., Stratton, K. G., Smith, J. L., Jensen, M. C., Turtle, C. J., Keenan, C., Annesley, C., Summers, C. N., Webb‐Robertson, B., Hirayama, A. V. V., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.05.003 · Cited by 6
CAR T‐cell therapy‐related neurotoxicity in paediatric acute lymphocytic leukaemia
Tan, A. P. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28635 · Cited by 6
CAR T Cell and BiTE Therapy—New Therapies, New Risks?
Chen, D. H., Tyebally, S. M., Mallouppas, M., & Ghosh, A. K. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00661-5 · Cited by 6
Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
Zhou, W., Chen, W., Wan, X., Luo, C., Du, X., Li, X., Chen, Q., Gao, R., Zhang, X., Xie, M., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.815679 · Cited by 6
Gavriilaki, E., Mallouri, D., Bousiou, Z., Demosthenous, C., Vardi, A., Dolgyras, P., Batsis, I., Stroggyli, E., Karvouni, P., Masmanidou, M., et al. (2023) · Cancers · doi:10.3390/cancers15174253 · Cited by 6
Genetically enhanced T lymphocytes and the intensive care unit
Tat, T., Li, H., Constantinescu, C.-S., Onaciu, A., Chira, S., Osan, C., Paşca, S., Petrushev, B., Moisoiu, V., Micu, W.-T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24637 · Cited by 6
Thibodeaux, S. R., & Milone, M. C. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2016.258988 · Cited by 7
Chimeric antigen receptor T-cell toxicity
Baymon, D. E., & Boyer, E. W. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000747 · Cited by 6
Hematopathologic Correlates of CAR T-Cell Therapy
Dolan, J. G., Paessler, M. E., Rheingold, S. R., & Pillai, V. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.03.012 · Cited by 6
Self-citationEmerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
Abuasab, T., Rowe, J. M., & Tvito, A. (2021) · Biologics · doi:10.2147/btt.s290294 · Cited by 6
Advanced Therapy Medicinal Products
Neuhaus, V., Schaudien, D., & Dehmel, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_143 · Cited by 6
Shen, D., Song, H., Xu, X., Xu, W., Wang, D., Liang, J. B., Fang, M., Liao, C., Chen, X., Li, S., et al. (2020) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1704325 · Cited by 6
Antibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis
Parrondo, R. D., Majeed, U., & Sher, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16697 · Cited by 6
Beck, M., Blumenberg, V., Bücklein, V., Bundschuh, R. A., Harrer, D. C., Hirschbühl, K., Jung, J., Kunz, W. G., Menhart, K., Winkelmann, M., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01201-1 · Cited by 5
Neuromuscular complications associated with cancer immunotherapy
Xiong, G., Lomen‐Hoerth, C., Richman, D. P., & Li, T. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.004 · Cited by 5
Gao, T. A., Shih, R. M., Clubb, J. D., Hung, S.-H., Singh, T., James‐Allan, L. B., DiBernardo, G., Shafer, A. M., Bouren, A., Ceja, M. A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw9286 · Cited by 7
Biomarker-empowered precision navigation of CAR-T cell therapy
Wang, Y., Cheng, W., Kang, K., Niu, T., Zhao, A., & Wu, Y. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02647-0 · Cited by 5
Inflammatory Biomarkers and Neurotransmitter Perturbations in Delirium
Maldonado, J. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-25751-4_10 · Cited by 6
Cardle, I. I., Scherer, D. R., Jensen, M. C., Pun, S. H., & Sellers, D. L. (2025) · ACS Nano · doi:10.1021/acsnano.4c16824 · Cited by 5
Tan, X., Wang, J., Chen, S., Liu, L., Li, Y., Tu, S., Yi, H., Zhou, J., Wang, S., Liu, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003479 · Cited by 5
Ng, S., Flaherty, P. W., Ancheta, M., Tindbaek, K., Sekhon, M. K., Huang, J. J., Portuguese, A. J., Albittar, A. A., Kopmar, N. E., Cowan, A. J., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.07.022 · Cited by 5
Gupta, S., Maude, S. L., O'Brien, M. M., Rau, R. E., & McNeer, J. L. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30443-2 · Cited by 6
Self-citation
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
